[1]»Æ¿¡»¨,¶Î»ª*.Hippo-YAPÐźÅͨ·²ÎÓ븾¿ÆÖ×ÁöµÄ·¢Éú·¢Õ¹[J].Öйú¼Æ»®ÉúÓýºÍ¸¾²ú¿Æ,2020,(2):29-32,40.

µã»÷¸´ÖÆ

Hippo-YAPÐźÅͨ·²ÎÓ븾¿ÆÖ×ÁöµÄ·¢Éú·¢Õ¹

·ÖÏíµ½£º

²Î¿¼ÎÄÏ×/References:

£Û1£ÝHansen C G M T, TAZ. A nexus for hippo signaling and beyond £ÛJ£Ý. Trends in Cell Biology, 2015, 25(9): 499-513. £Û2£ÝHe Chunbo, Lv Xiangmin, Huang Cong, et al. YAP1-LATS2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis £ÛJ£Ý. EMBO Reports, 2019, 20(3):e 44948. £Û3£ÝSmall W, Bacon M A, Bajaj A, et al. Cervical cancer: A global health crisis £ÛJ£Ý. Cancer, 2017, 123(13): 2404-2412. £Û4£ÝLiu Tianbo, Liu Yunduo, Gao Hongyu, et al. Clinical significance of Yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes £ÛJ£Ý.International Journal of Gynecological Cancer, 2013,23(4):735- 742. £Û5£ÝHe Chunbo, Mao Dagan, Hua Guohua, et al. The hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression £ÛJ£Ý. EMBO Molecular Medicine, 2015, 7(11): 1426-1449. £Û6£ÝXiao Hong, Wu Lin-a, Zheng Hui-xia, et al. Expression of Yes-associated protein in cervical squamous epithelium lesions £ÛJ£Ý. International Journal of Gynecological Cancer, 2014, 24(9): 1575-1582. £Û7£ÝBuglioni S, Vici P, Sergi D, et al. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment £ÛJ£Ý.Oncoimmunology,2016,5(6):e 1160187. £Û8£ÝDeng Jihong, Zhang Wen, Liu Shuangyue, et al. LATS1 suppresses proliferation and invasion of cervical cancer £ÛJ£Ý. Molecular Medicine Reports, 2017, 15(4): 1654-1660. £Û9£ÝZhan Ping, Liu Ling, Liu Bin, et al. Expression of integrin ¦Â1 and its significance in squamous cell carcinoma of the cervix £ÛJ£Ý. Molecular Medicine Reports, 2014, 9(6): 2473-2478. £Û10£ÝLiu Yaofang, Ren Meiping, TAN Xiaoyong, et al. Distinct changes in the expression TAZ are associated with normal cervix and human cervical cancer £ÛJ£Ý. Journal of Cancer, 2018, 9(22): 4263-4270. £Û11£ÝDiaz-Padilla I, Monk B J, Mackay H J, et al. Treatment of metastatic cervical cancer: future directions involving targeted agents £ÛJ£Ý. Critical Reviews in Oncology Hematology, 2013, 85(3): 303-314. £Û12£ÝLorusso D, Petrelli F, Coinu A, et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer £ÛJ£Ý. Gynecologic Oncology, 2014, 133(1): 117-123. £Û13£ÝShen Ding-wu, Pouliont L M, Hall M D, et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes £ÛJ£Ý. Pharmacological Reviews, 2012, 64(3): 706-721. £Û14£ÝJagannathan R, Schimizzi G V, Zhang K, et al. AJUBA lim proteins limit hippo activity in proliferating cells by sequestering the hippo core kinase complex in the cytosol £ÛJ£Ý. Molecular and Cellular Biology,2016,36(20):2526-2542. £Û15£ÝShi Xuejiao, Chen Zhaoli, Hu Xueda, et al. AJUBA promotes the migration and invasion of esophageal squamous cell carcinoma cells through upregulation of MMP10 and MMP13 expression £ÛJ£Ý. Oncotarget, 2016, 7(24): 36407-36418. £Û16£ÝBi Lihong, Ma Feng, Tina Rui, et al. AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer £ÛJ£Ý. Gene, 2018, 644: 148-154. £Û17£ÝSehouli J, Alvarez A M, Manouchehrpour S, et al. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer £ÛJ£Ý. Gynecologic Oncology, 2012, 124(2): 205-209. £Û18£ÝSch¨¹ler S, Lattrich C, Skrzypczak M, et al. Icb-1 gene polymorphism rs1467465 is associated with susceptibility to ovarian cancer £ÛJ£Ý. Journal of Ovarian Research, 2014, 7(1): 42. £Û19£ÝChen L-p, Cai P-s, Liang H-b. Association of the genetic polymorphisms of NFKB1 with susceptibility to ovarian cancer £ÛJ£Ý. Genetics and Molecular Research : GMR, 2015, 14(3): 8273-8282. £Û20£ÝZhang X, George J, Deb S, et al. The hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene £ÛJ£Ý. Oncogene, 2011, 30(25): 2810-2822. £Û21£ÝHe C, Lv X, Hua G, et al. YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression £ÛJ£Ý. Oncogene, 2015, 34(50): 6040-6054. £Û22£ÝXia Yan, Chang Ting, Wang Yingmei, et al. Correction: YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients £ÛJ£Ý. PLOS One, 2016, 11(3): e 0152712. £Û23£ÝSpiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid £ÛJ£Ý. Nature Reviews Molecular Cell Biology, 2003, 4(5): 397-407. £Û24£ÝSutphen R, Xu Yan, Wilbanks G D, et al. Lysophospholipids are potential biomarkers of ovarian cancer £ÛJ£Ý. Cancer Epidemiology, Biomarkers & Prevention, 2004, 13(7): 1185-1191. £Û25£ÝLi Jun, Ye Lin, Owen S, et al. Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (Review) £ÛJ£Ý. International Journal of Molecular Medicine,2015,36(6):1451-1463. £Û26£ÝFan Qianlan,Cheng Yuan,Chang H M,et al.Sphingosine-1-phosphate promotes ovarian cancer cell proliferation by disrupting Hippo signaling £ÛJ£Ý. Oncotarget, 2017, 8(16): 27166-27176. £Û27£ÝSchoenherr C J, Anderson D J. The neuron-restrictive silencer factor (NRSF):a coordinate repressor of multiple neuron-specific genes £ÛJ£Ý. Science (New York, N.Y.), 1995, 267(5202): 1360-1363. £Û28£ÝDeng Pengfei, Zuo Yan, Feng Shuxian, et al. Knockdown of NRSF inhibits cell proliferation of ovarian cancer via activating Hippo pathway £ÛJ£Ý. Life Sciences, 2018, 215: 73-79. £Û29£ÝXie Yao, Zhou Fei, Zhao Xia. TNFAIP8 promotes cell growth by regulating the Hippo pathway in epithelial ovarian cancer £ÛJ£Ý. Experimental and Therapeutic Medicine, 2018, 16(6): 4975-4982. £Û30£ÝBartel D P. MicroRNAs: target recognition and regulatory functions £ÛJ£Ý. Cell, 2009, 136(2): 215-233. £Û31£ÝXu Man-man, Xiao Juan, Chen Ming, et al. miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the hippo signaling pathway £ÛJ£Ý. International Journal of Oncology, 2018, 52(3): 815-827. £Û32£ÝArnold M,Pandeya N,Byrnes G,et al.Global burden of cancer attributable to high body-mass index in 2012:a populationbased study £ÛJ£Ý. The Lancet Oncology, 2015, 16(1): 36-46. £Û33£ÝChen Wanqing, Zheng Rongshou, Baade P D, et al. Cancer statistics in China, 2015 £ÛJ£Ý. CA-A Cancer Journal for Clinicians, 2016, 66(2): 115-132. £Û34£ÝMitamura T, Watari H, Wang Lei, et al. microRNA 31 functions as an endometrial cancer oncogene by suppressing hippo tumor suppressor pathway £ÛJ£Ý. Molecular Cancer, 2014, 13: 97. £Û35£ÝTsujiura M, Mazack V, Sudol M, et al. Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer £ÛJ£Ý. PLOS One, 2014, 9(6): e 100974. £Û36£ÝRomero-P¨¦rez L, Garcia-Sanz P, MOTA A, et al. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer £ÛJ£Ý. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology,Inc,2015,28(11):1492-1503. £Û37£ÝChe Xiaoxia, Jian Fangfang, Jia Nan, et al. FAT4-USP51 complex regulates the proliferation and invasion of endometrial cancer via Hippo pathway £ÛJ£Ý. American Journal of Translational Research, 2019, 11(5): 2784-2800. £Û38£ÝTian Wen-yan, Teng Fei, Zhao Jing, et al. Estrogen and insulin synergistically promote type 1 endometrial cancer progression £ÛJ£Ý. Cancer Biology & Therapy, 2017, 18(12): 1000-1010. £Û39£ÝWang Chao, Jeong K, Jiang Hongyuan, et al. YAP/TAZ regulates the insulin signaling via IRS1/2 in endometrial cancer £ÛJ£Ý. American Journal of Cancer Research, 2016, 6(5): 996-1010.